TanHL的个人主页 - 老虎社区

TanHL

暂无个人介绍

IP属地：未知

3关注

2粉丝

0主题

0勋章

2021-07-01

This is my reward

2021-06-27

Thanks for sharing

抱歉，原内容已删除

2021-06-27

Thanks

抱歉，原内容已删除

2021-06-15

Hi

抱歉，原内容已删除

2021-06-15

Hi

抱歉，原内容已删除

2021-06-15

Yes

抱歉，原内容已删除

2021-06-15

Hi

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up

2021-06-15

Hi

抱歉，原内容已删除

2021-06-14

Morning

Palantir Stock In 5 Years: What To Consider

2021-06-14

Thanks

抱歉，原内容已删除

2021-06-14

Monitor closely

抱歉，原内容已删除

2021-06-14

Thanks

抱歉，原内容已删除

2021-06-14

Thanks

抱歉，原内容已删除

2021-06-14

Yes

Blue Origin auctions seat on first spaceflight with Jeff Bezos for $28 million

2021-06-14

Awaiting for the game

抱歉，原内容已删除

2021-06-14

Morning

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583732088443383","uuid":"3583732088443383","gmtCreate":1620643338675,"gmtModify":1620643338675,"name":"TanHL","pinyin":"tanhl","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":3,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":151694788,"gmtCreate":1625077624644,"gmtModify":1631891633641,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"This is my reward&nbsp;","listText":"This is my reward&nbsp;","text":"This is my reward","images":[{"img":"https://static.tigerbbs.com/2f99972d9d6d60790b46f7bec41f4e14","width":"750","height":"1238"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151694788","isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":124355260,"gmtCreate":1624748677350,"gmtModify":1631891633656,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/124355260","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124359059,"gmtCreate":1624748159971,"gmtModify":1631891633671,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124359059","repostId":"1198714523","repostType":2,"isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187217979,"gmtCreate":1623755280491,"gmtModify":1631891633691,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187217979","repostId":"1184288080","repostType":4,"isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187214827,"gmtCreate":1623755261769,"gmtModify":1631891633707,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187214827","repostId":"1122638224","repostType":4,"isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187215232,"gmtCreate":1623755239526,"gmtModify":1631891633721,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187215232","repostId":"1114926830","repostType":4,"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187215059,"gmtCreate":1623755221371,"gmtModify":1631891633728,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/187215059","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187212117,"gmtCreate":1623755201339,"gmtModify":1631891633745,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187212117","repostId":"1135158450","repostType":4,"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185977115,"gmtCreate":1623632094237,"gmtModify":1631891633761,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Morning&nbsp;","listText":"Morning&nbsp;","text":"Morning","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185977115","repostId":"1135926549","repostType":4,"repost":{"id":"1135926549","kind":"news","pubTimestamp":1623630467,"share":"https://www.laohu8.com/m/news/1135926549?lang=&edition=full","pubTime":"2021-06-14 08:27","market":"us","language":"en","title":"Palantir Stock In 5 Years: What To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=1135926549","media":"seekingalpha","summary":"Summary\n\nPalantir Technologies, for all the furore surrounding the stock, is simply an enterprise so","content":"<p><b>Summary</b></p>\n<ul>\n <li>Palantir Technologies, for all the furore surrounding the stock, is simply an enterprise software business, and a good one to boot.</li>\n <li>Financial fundamentals are much better than the company is usually given credit for, and the stock price is, we believe, at an attractive buy point.</li>\n <li>In our view, the key with this name is to ignore all the noise on your stock board of choice.</li>\n <li>Looking five years out, we think this stock can be a huge winner, and we hold the name in staff personal accounts as a result.</li>\n <li>We remain at Buy on Palantir.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bb61d2356557cc39d32afc673a3ff65b\" tg-width=\"1536\" tg-height=\"864\" referrerpolicy=\"no-referrer\"><span>kanawatvector/iStock via Getty Images</span></p>\n<p><b>Make Like A Palantirian - Focus On The Signal, Not The Noise</b></p>\n<p>If you talk to users of Palantir Technologies(NYSE:PLTR)software, and we have, they will tell you that the main benefit of the company's technology is that it is able to pull together data from multiple sources and make sense of it all both quickly and easily. It does not require armies of business or data analysts sat in the basement to produce reports digestible by the folks in the big offices on the top floor. This means that correctly deployed, the products offer the dream of analytics companies since the days when \"extract, transform, load\" was new and cool - reduced cost of report production and increased actionability of those reports. Thus far we have yet to talk to a user that didn't think the software had changed their business for the better. No doubt there are some dissatisfied users, but we've yet to speak to any.</p>\n<p>Partly of the management team's own making (\"we love retail investors\"), partly due to the \"master of the dark arts\" reputation the company had fostered during its long gestation period as a privately-owned, CIA-backed business, and partly due to the zeitgeist, Palantir is an incredibly well-followed stock and one that seemingly causes angst amongst shareholders and non-shareholders alike. Just go check your favorite stock board and see the screeching. Our choice of poison is the PLTR board on StockTwits, which ishere. We can use this as an example of the strangely high level of interest in this enterprise software stock. It has 168k followers on that board, which compared to others on the platform is half as many as Microsoft and perhaps of more relevance, more than half as many as the current meme favorite, AMC. And the posts are absolutely breathless. Again, this is an enterprise software company, not an altcoin.</p>\n<p>If you own PLTR stock or are thinking of doing so, our exhortation to you would be to take a step back, calm down, and with a cool head look at the numbers and the stock chart. This is our approach, and it has lead to the name being a high-conviction favorite of ours. When the stock has swooned, we're relaxed; if it moves up in the coming days and weeks, we'll be relaxed. Palantir is, we think, a very strong long term hold stock. If we can leave you with one thought after you read our analysis, it would be: focus on the signal, ignore the noise. And that, after all, is what Palantir Technologies customers pay it to help them do. As a shareholder? The stock can pay you for doing the same.</p>\n<p><b>PLTR Stock Price</b></p>\n<p>Let's first take a look at PLTR's stock price and its evolution since the direct listing last year. It has, in short, been rather volatile.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9c352517d3fdee0325a7ed80cfe61207\" tg-width=\"640\" tg-height=\"379\"><span>Source: YCharts.com</span></p>\n<p>It's the volatility that leads to some of the stock board screeching. But if you just step back you would say that thus far this has been a terrifically successful direct listing, with the stock up 150% since then, versus mid-20s% total returns from the main indices (we use the SPY and QQQ ETFs above as proxies for the S&amp;P500 and the Nasdaq respectively).</p>\n<p>If you look shorter term, since the February 2021 highs, you can see more cause for concern among short-term holders. This chart runs from 1 February this year, to date.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0b6e221de3f33956330342f0010cb029\" tg-width=\"640\" tg-height=\"381\"><span>Source: YCharts.com</span></p>\n<p>Since, inevitably, many people buy near the top of a run, this means there are many holders sat on a loss and hoping for a recovery, and probably many that have sold, absorbing the loss. As always, if you zoom too far in, you can miss the big picture. We believe Palantir stock has a very bright future.</p>\n<p><b>Palantir Valuation</b></p>\n<p>By way of background, here's the numbers on PLTR. The table below is patchy because as a new issue, it takes time for the company's SEC reports to build up a picture of the past. In 3-4 quarters' time we will be able to see a much clearer picture of the quarter-to-quarter history and how the growth flywheel is moving. First, revenue down to EBITDA.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ef965d0aa18087da24ed87c59e9377a\" tg-width=\"505\" tg-height=\"680\"><span>Source: Company SEC filings,YCharts.com, Cestrian Analysis</span></p>\n<p>Now, capex down to net debt and remaining performance obligation.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/07de8f157aa9059c61db0a5fdcacbcc4\" tg-width=\"496\" tg-height=\"411\"><span>Source: Company SEC filings,YCharts.com, Cestrian Analysis</span></p>\n<p>The first half of 2021 has been characterized by a material selloff in growth names, with value stocks being the principal beneficiary. In recent weeks, the market has become a little kinder to growth names and in our house view, that will persist for the remainder of the year. Palantir's valuation multiples have moved up materially of late, which partly reflects the market's warming towards growth names, and partly the improvement in PLTR's own growth rates that you see above.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eade11b880c661731fab7c27c81d528f\" tg-width=\"640\" tg-height=\"378\"><span>Source: YCharts.com</span></p>\n<p>Folks get all steamed up about valuation multiples - is stock X<i>really</i>worth Y times revenue or Z times cashflow? - but in truth, there is no science to it. In a bull market for growth names, the faster you grow and the more profitably you do it and the more visibility you have into future growth, the more expensive your stock, relative to other such stocks. In valuation, everything is relative, there are no absolutes. Ten years ago, paying 10x TTM revenue for a software company was considered expensive, today, plenty trade at 40x TTM revenue plus. It just is what it is.</p>\n<p>Palantir today trades at the following multiples:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddbc7d4aca650c4e6b406c336671ec9b\" tg-width=\"246\" tg-height=\"299\"><span>Source: Company SEC filings, YCharts.com, Cestrian Analysis</span></p>\n<p>The EBITDA and cashflow multiples are clearly absurd if you think that discounted cashflow is any kind of way to measure stock valuations, but since we think DCF is about as relevant to valuing growth names as is the color of the company's logo, we don't take any notice of that. 35x TTM revenue for a business with long-lived government and corporate contracts, the demonstrated ability to generate both accounting and cash profits, and growing revenue at 49% in Q1 vs the prior year Q1? In the current market context that seems fine to us.</p>\n<p><b>Is Palantir A Long-Term Stock?</b></p>\n<p>So, is Palantir a good long-term stock? We find scant assistance from sell-side analyst targets which seem to range from $17-30 looking twelve months out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f3ef1518eb94d1152c976ad16e462bb\" tg-width=\"640\" tg-height=\"223\"><span>Source: TipRanks</span></p>\n<p>We think the answer lies in doing two kinds of actual analysis (as opposed to just deciding the stock might move up a few dollars or down a few dollars which appears to be the basis of price targets!).</p>\n<p><b>Palantir Stock Forecast In 5 Years</b></p>\n<p><b>Fundamental Analysis</b></p>\n<p>The first kind of analysis we think is helpful here is to consider the fundamentals. Here we take the management team's commentary on likely forward growth rates (they target 30% long-run growth), but jacked them<i>up</i>a little because we think the team is sandbagging somewhat. We then assign rising EBITDA margins, cap them at what used to be about right for a well-run enterprise software and services business - 20% - it's quite possible that PLTR can beat this if they hand over much of the services work to consultant partners over time, but let's say 20% terminal EBITDA margins for now. Then we assign a cautious rate of conversion of EBITDA into unlevered pre-tax free cashflow (= EBITDA - capex - change in working capital) such that around 20% of EBITDA leaks into the ether somehow. (This is just a way to model cash generation conservatively. If 20% leaked somewhere it would show up on the balance sheet in poor receivables or huge prepayments or something else. It's a modeling device, it's not real).</p>\n<p>Back to valuation multiples for a moment.</p>\n<p>Where valuation multiples<i>do</i>matter is in the direction of travel between the time you buy a stock and the time you sell it. If multiples expand, that is the greatest source of free money you ever could hope for. Alchemy has nothing on multiple expansion. And if they compress, you can own a company performing wonderfully on its financial statements yet its stock may just not move up at all, or, worse, go down. From a fundamentals perspective, this is the key question long term investors need to ask of PLTR stock. In our house view the company will continue to perform well. The principal risk to returns comes from whether multiples will expand, compress, or stay level. In our 5-year outlook we assume those multiples will tail off somewhat. That's not based on any Fed-whispering, inflation analysis, velocity of money circulation enquiry or anything like that. It's just a modestly cautious modeling device. Multiples could go up a lot, down a lot, stay flat. Who knows. But you have to come up with some assumptions to forecast a stock on fundamentals, so, these are our working assumptions.</p>\n<p>Put all that stuff together could point to a runup from $24 today to $50 or so in 2024, and on to $60 or so in 2025. Now, compared to playingmeme stockswith the best of them, that's not very exciting. But compared to most periods of investing in stocks, doubling your money in three years isn't so bad.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d4e004057976b6da047f994b01b5a99\" tg-width=\"439\" tg-height=\"288\"><span>Source: Company SEC filings,YCharts.com, Cestrian Analysis</span></p>\n<p>From a fundamentals point of view, we see the key risks as fairly simple. One, can the company get out of its own way, meaning, can it execute an increasing pure software model, farming more and more services out to integrator partners. We really do not want to see the company making its numbers by selling consulting time - that's not scalable and is as a result not worth anything like the kinds of multiples above, which assume a software business model. And two, will those multiples hold up. So, quarter to quarter, in our live coverage of the business, that's what we're looking at. Revenue growth vs. gross margin vs. UFCF margins (that tells you all you need to know about the type of revenue and its valuation potential), and, prevailing market multiples for growth names.</p>\n<p><b>Chart Analysis</b></p>\n<p>Chart analysis is particularly relevant to the near term outlook for PLTR and that is itself relevant to the long term, because very often the prevailing view on this name seems to be something highly analytical like, \"it will never see $40 again lol\". The fact that the stock is a little stuck below $25 despite improving fundamentals and a thawing market for growth names isn't any kind of magic. It's just simple demand and supply. The chart below shows you that in that $25 zip code there have been a<i>whole</i>lot of shares traded in the past. And we know that PLTR is a favorite of retail - that 168k follower number above tells you that. And we know that diamond hands are something of a myth among retail investors. When markets drop hard like growth did in H1 2021, then come back, you very often can find folks very happy just to make their money back, or most of it. Relieved, having bought PLTR at say $25-30, folks start selling, because at one point they were looking at a $17 handle and saying, please don't send me a margin call now, pretty please.</p>\n<p>This chart looks horribly complicated, but like all stock charts, it isn't really, once you free your mind and think about what it is telling you about what market participants are doing.</p>\n<p>If you think stock charts are bunk, they aren't. Prepared correctly they can sometimes tell you a<i>lot</i>about the future direction of a stock. So, even if you think this is just some kind of kindergarten coloring-in contest which has gotten carried away with itself, bear with us.</p>\n<p>We think this chart on PLTR is a beauty. Because we think it tells you that with any kind of market tailwind, once PLTR pushes up to $30 or so, it can fly much further. Much further. And since our fundamental analysis tells us that $50-60/share is possible, that our chart says that $30 is surmountable, is another piece of evidence for us that indicates this can be very good long term investment.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/46156df04fcc804d791f980313140d41\" tg-width=\"640\" tg-height=\"299\"><span>Source: TradingView, Cestrian Analysis</span></p>\n<p>Now, if you are an actual technical analyst you can skip what follows because either (1) you already figured it or more likely (2) you have a different and better take on the chart on account of being an actual technical analyst. We aren't technical analysts. We just like messing about with Crayolas. But this is our take:</p>\n<ul>\n <li>This chart shows the whole period from direct listing to today.</li>\n <li>The wide colored horizontal bands show something called the Fibonacci retracement levels. That's a complicated way of saying, if you look at the runup of the stock from its lows to its highs, at what levels on the way back down is it likely to find support? Due to (i) some poorly-understood interlinking between absolute numbers and mammalian brain structure (no, really) and more importantly (ii) the fact that everybody trades according to Fib levels, you can see PLTR find support on the way back down at firstly the 50% retracement (= lost half the value gained on the runup) briefly during February, then it drops quickly to the 61.8% retracement level in late February and hovers around it till early May, whereupon it really starts digging and nearly hits the 78.6% retracement level. That is one big ol selloff, too much by any measure, which is why you see that big, fast reversal on May 11. And allowing for a little oscillation, the stock has moved up since then.</li>\n <li>The upward-sloping thick black line on the right hand side of the chart shows you a rising support level through May and June. The stock is making higher lows each day, which is bullish.</li>\n <li>Now the interesting part. Those blue and yellow lines protruding from right to left tell you the historic volumes of stock traded at any given price. The thick black horizontal line is the \"point of control\" ie. the center of gravity of all those sales. And, lo and behold, between that rising support line and the point of control line, you can see the stock moving up and wanting to punch up through that point of control line. Which is, as you can see, a line of resistance or support stretching back to November 2020. This is why we<i>love</i>stock charts, because of the magic they sometimes reveal.</li>\n <li>Palantir stock is in a firefight between bulls and bears right now. Every time it moves up some, you have a whole lot of people saying, phew and double phew I got my money back or most of it, and selling. And that rush to liquidate is holding up the stock's move upwards. But sooner or later, in our view, the supply of shares for sale will dry up. Because, one, the market is warming to growth names and, two, PLTR is doing well on its fundamentals and is likely to see some improved sentiment around the market. So if the stock can push up to where you see relatively few stocks traded, relatively few disappointed owners - the $30 zone and beyond - then we think the relentless supply of \"for sale\" shares is likely to dry up. And<i>that</i>means the stock can move up much more easily from say $30-40 than it can from $20-30.</li>\n</ul>\n<p>So, our view here is simple. Company fundamentals strong and improving. Market backdrop, warming towards growth names. Stock chart saying, just a little bit further now, just a little more supply of shares-for-sale from \"weak hands\" as the meme fraternity likes to say, and then this stock can really move up.</p>\n<p><b>Is Palantir Stock A Buy, Sell Or Hold Now?</b></p>\n<p>If you bought the stock at $40-something and your best-friend-turned-nemesis broker is calling asking for their margin back, well, you may not have a choice. But if you do have a choice in the matter, and you have a time horizon longer than the weekend (which, diamond hands notwithstanding, seems to be the extent of the meme community's outlook), we think PLTR stock is a resounding Buy. Fundamentals good, chart good, market improving, whole bunch of retail investors likely to suddenly warm up to the stock once it does start making a move, whole bunch of institutions likely to be buying in during this consolidation period. Buy.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir Stock In 5 Years: What To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir Stock In 5 Years: What To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 08:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434399-palantir-stock-5-years><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPalantir Technologies, for all the furore surrounding the stock, is simply an enterprise software business, and a good one to boot.\nFinancial fundamentals are much better than the company is ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434399-palantir-stock-5-years\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4434399-palantir-stock-5-years","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135926549","content_text":"Summary\n\nPalantir Technologies, for all the furore surrounding the stock, is simply an enterprise software business, and a good one to boot.\nFinancial fundamentals are much better than the company is usually given credit for, and the stock price is, we believe, at an attractive buy point.\nIn our view, the key with this name is to ignore all the noise on your stock board of choice.\nLooking five years out, we think this stock can be a huge winner, and we hold the name in staff personal accounts as a result.\nWe remain at Buy on Palantir.\n\nkanawatvector/iStock via Getty Images\nMake Like A Palantirian - Focus On The Signal, Not The Noise\nIf you talk to users of Palantir Technologies(NYSE:PLTR)software, and we have, they will tell you that the main benefit of the company's technology is that it is able to pull together data from multiple sources and make sense of it all both quickly and easily. It does not require armies of business or data analysts sat in the basement to produce reports digestible by the folks in the big offices on the top floor. This means that correctly deployed, the products offer the dream of analytics companies since the days when \"extract, transform, load\" was new and cool - reduced cost of report production and increased actionability of those reports. Thus far we have yet to talk to a user that didn't think the software had changed their business for the better. No doubt there are some dissatisfied users, but we've yet to speak to any.\nPartly of the management team's own making (\"we love retail investors\"), partly due to the \"master of the dark arts\" reputation the company had fostered during its long gestation period as a privately-owned, CIA-backed business, and partly due to the zeitgeist, Palantir is an incredibly well-followed stock and one that seemingly causes angst amongst shareholders and non-shareholders alike. Just go check your favorite stock board and see the screeching. Our choice of poison is the PLTR board on StockTwits, which ishere. We can use this as an example of the strangely high level of interest in this enterprise software stock. It has 168k followers on that board, which compared to others on the platform is half as many as Microsoft and perhaps of more relevance, more than half as many as the current meme favorite, AMC. And the posts are absolutely breathless. Again, this is an enterprise software company, not an altcoin.\nIf you own PLTR stock or are thinking of doing so, our exhortation to you would be to take a step back, calm down, and with a cool head look at the numbers and the stock chart. This is our approach, and it has lead to the name being a high-conviction favorite of ours. When the stock has swooned, we're relaxed; if it moves up in the coming days and weeks, we'll be relaxed. Palantir is, we think, a very strong long term hold stock. If we can leave you with one thought after you read our analysis, it would be: focus on the signal, ignore the noise. And that, after all, is what Palantir Technologies customers pay it to help them do. As a shareholder? The stock can pay you for doing the same.\nPLTR Stock Price\nLet's first take a look at PLTR's stock price and its evolution since the direct listing last year. It has, in short, been rather volatile.\nSource: YCharts.com\nIt's the volatility that leads to some of the stock board screeching. But if you just step back you would say that thus far this has been a terrifically successful direct listing, with the stock up 150% since then, versus mid-20s% total returns from the main indices (we use the SPY and QQQ ETFs above as proxies for the S&P500 and the Nasdaq respectively).\nIf you look shorter term, since the February 2021 highs, you can see more cause for concern among short-term holders. This chart runs from 1 February this year, to date.\nSource: YCharts.com\nSince, inevitably, many people buy near the top of a run, this means there are many holders sat on a loss and hoping for a recovery, and probably many that have sold, absorbing the loss. As always, if you zoom too far in, you can miss the big picture. We believe Palantir stock has a very bright future.\nPalantir Valuation\nBy way of background, here's the numbers on PLTR. The table below is patchy because as a new issue, it takes time for the company's SEC reports to build up a picture of the past. In 3-4 quarters' time we will be able to see a much clearer picture of the quarter-to-quarter history and how the growth flywheel is moving. First, revenue down to EBITDA.\nSource: Company SEC filings,YCharts.com, Cestrian Analysis\nNow, capex down to net debt and remaining performance obligation.\nSource: Company SEC filings,YCharts.com, Cestrian Analysis\nThe first half of 2021 has been characterized by a material selloff in growth names, with value stocks being the principal beneficiary. In recent weeks, the market has become a little kinder to growth names and in our house view, that will persist for the remainder of the year. Palantir's valuation multiples have moved up materially of late, which partly reflects the market's warming towards growth names, and partly the improvement in PLTR's own growth rates that you see above.\nSource: YCharts.com\nFolks get all steamed up about valuation multiples - is stock Xreallyworth Y times revenue or Z times cashflow? - but in truth, there is no science to it. In a bull market for growth names, the faster you grow and the more profitably you do it and the more visibility you have into future growth, the more expensive your stock, relative to other such stocks. In valuation, everything is relative, there are no absolutes. Ten years ago, paying 10x TTM revenue for a software company was considered expensive, today, plenty trade at 40x TTM revenue plus. It just is what it is.\nPalantir today trades at the following multiples:\nSource: Company SEC filings, YCharts.com, Cestrian Analysis\nThe EBITDA and cashflow multiples are clearly absurd if you think that discounted cashflow is any kind of way to measure stock valuations, but since we think DCF is about as relevant to valuing growth names as is the color of the company's logo, we don't take any notice of that. 35x TTM revenue for a business with long-lived government and corporate contracts, the demonstrated ability to generate both accounting and cash profits, and growing revenue at 49% in Q1 vs the prior year Q1? In the current market context that seems fine to us.\nIs Palantir A Long-Term Stock?\nSo, is Palantir a good long-term stock? We find scant assistance from sell-side analyst targets which seem to range from $17-30 looking twelve months out.\nSource: TipRanks\nWe think the answer lies in doing two kinds of actual analysis (as opposed to just deciding the stock might move up a few dollars or down a few dollars which appears to be the basis of price targets!).\nPalantir Stock Forecast In 5 Years\nFundamental Analysis\nThe first kind of analysis we think is helpful here is to consider the fundamentals. Here we take the management team's commentary on likely forward growth rates (they target 30% long-run growth), but jacked themupa little because we think the team is sandbagging somewhat. We then assign rising EBITDA margins, cap them at what used to be about right for a well-run enterprise software and services business - 20% - it's quite possible that PLTR can beat this if they hand over much of the services work to consultant partners over time, but let's say 20% terminal EBITDA margins for now. Then we assign a cautious rate of conversion of EBITDA into unlevered pre-tax free cashflow (= EBITDA - capex - change in working capital) such that around 20% of EBITDA leaks into the ether somehow. (This is just a way to model cash generation conservatively. If 20% leaked somewhere it would show up on the balance sheet in poor receivables or huge prepayments or something else. It's a modeling device, it's not real).\nBack to valuation multiples for a moment.\nWhere valuation multiplesdomatter is in the direction of travel between the time you buy a stock and the time you sell it. If multiples expand, that is the greatest source of free money you ever could hope for. Alchemy has nothing on multiple expansion. And if they compress, you can own a company performing wonderfully on its financial statements yet its stock may just not move up at all, or, worse, go down. From a fundamentals perspective, this is the key question long term investors need to ask of PLTR stock. In our house view the company will continue to perform well. The principal risk to returns comes from whether multiples will expand, compress, or stay level. In our 5-year outlook we assume those multiples will tail off somewhat. That's not based on any Fed-whispering, inflation analysis, velocity of money circulation enquiry or anything like that. It's just a modestly cautious modeling device. Multiples could go up a lot, down a lot, stay flat. Who knows. But you have to come up with some assumptions to forecast a stock on fundamentals, so, these are our working assumptions.\nPut all that stuff together could point to a runup from $24 today to $50 or so in 2024, and on to $60 or so in 2025. Now, compared to playingmeme stockswith the best of them, that's not very exciting. But compared to most periods of investing in stocks, doubling your money in three years isn't so bad.\nSource: Company SEC filings,YCharts.com, Cestrian Analysis\nFrom a fundamentals point of view, we see the key risks as fairly simple. One, can the company get out of its own way, meaning, can it execute an increasing pure software model, farming more and more services out to integrator partners. We really do not want to see the company making its numbers by selling consulting time - that's not scalable and is as a result not worth anything like the kinds of multiples above, which assume a software business model. And two, will those multiples hold up. So, quarter to quarter, in our live coverage of the business, that's what we're looking at. Revenue growth vs. gross margin vs. UFCF margins (that tells you all you need to know about the type of revenue and its valuation potential), and, prevailing market multiples for growth names.\nChart Analysis\nChart analysis is particularly relevant to the near term outlook for PLTR and that is itself relevant to the long term, because very often the prevailing view on this name seems to be something highly analytical like, \"it will never see $40 again lol\". The fact that the stock is a little stuck below $25 despite improving fundamentals and a thawing market for growth names isn't any kind of magic. It's just simple demand and supply. The chart below shows you that in that $25 zip code there have been awholelot of shares traded in the past. And we know that PLTR is a favorite of retail - that 168k follower number above tells you that. And we know that diamond hands are something of a myth among retail investors. When markets drop hard like growth did in H1 2021, then come back, you very often can find folks very happy just to make their money back, or most of it. Relieved, having bought PLTR at say $25-30, folks start selling, because at one point they were looking at a $17 handle and saying, please don't send me a margin call now, pretty please.\nThis chart looks horribly complicated, but like all stock charts, it isn't really, once you free your mind and think about what it is telling you about what market participants are doing.\nIf you think stock charts are bunk, they aren't. Prepared correctly they can sometimes tell you alotabout the future direction of a stock. So, even if you think this is just some kind of kindergarten coloring-in contest which has gotten carried away with itself, bear with us.\nWe think this chart on PLTR is a beauty. Because we think it tells you that with any kind of market tailwind, once PLTR pushes up to $30 or so, it can fly much further. Much further. And since our fundamental analysis tells us that $50-60/share is possible, that our chart says that $30 is surmountable, is another piece of evidence for us that indicates this can be very good long term investment.\nSource: TradingView, Cestrian Analysis\nNow, if you are an actual technical analyst you can skip what follows because either (1) you already figured it or more likely (2) you have a different and better take on the chart on account of being an actual technical analyst. We aren't technical analysts. We just like messing about with Crayolas. But this is our take:\n\nThis chart shows the whole period from direct listing to today.\nThe wide colored horizontal bands show something called the Fibonacci retracement levels. That's a complicated way of saying, if you look at the runup of the stock from its lows to its highs, at what levels on the way back down is it likely to find support? Due to (i) some poorly-understood interlinking between absolute numbers and mammalian brain structure (no, really) and more importantly (ii) the fact that everybody trades according to Fib levels, you can see PLTR find support on the way back down at firstly the 50% retracement (= lost half the value gained on the runup) briefly during February, then it drops quickly to the 61.8% retracement level in late February and hovers around it till early May, whereupon it really starts digging and nearly hits the 78.6% retracement level. That is one big ol selloff, too much by any measure, which is why you see that big, fast reversal on May 11. And allowing for a little oscillation, the stock has moved up since then.\nThe upward-sloping thick black line on the right hand side of the chart shows you a rising support level through May and June. The stock is making higher lows each day, which is bullish.\nNow the interesting part. Those blue and yellow lines protruding from right to left tell you the historic volumes of stock traded at any given price. The thick black horizontal line is the \"point of control\" ie. the center of gravity of all those sales. And, lo and behold, between that rising support line and the point of control line, you can see the stock moving up and wanting to punch up through that point of control line. Which is, as you can see, a line of resistance or support stretching back to November 2020. This is why welovestock charts, because of the magic they sometimes reveal.\nPalantir stock is in a firefight between bulls and bears right now. Every time it moves up some, you have a whole lot of people saying, phew and double phew I got my money back or most of it, and selling. And that rush to liquidate is holding up the stock's move upwards. But sooner or later, in our view, the supply of shares for sale will dry up. Because, one, the market is warming to growth names and, two, PLTR is doing well on its fundamentals and is likely to see some improved sentiment around the market. So if the stock can push up to where you see relatively few stocks traded, relatively few disappointed owners - the $30 zone and beyond - then we think the relentless supply of \"for sale\" shares is likely to dry up. Andthatmeans the stock can move up much more easily from say $30-40 than it can from $20-30.\n\nSo, our view here is simple. Company fundamentals strong and improving. Market backdrop, warming towards growth names. Stock chart saying, just a little bit further now, just a little more supply of shares-for-sale from \"weak hands\" as the meme fraternity likes to say, and then this stock can really move up.\nIs Palantir Stock A Buy, Sell Or Hold Now?\nIf you bought the stock at $40-something and your best-friend-turned-nemesis broker is calling asking for their margin back, well, you may not have a choice. But if you do have a choice in the matter, and you have a time horizon longer than the weekend (which, diamond hands notwithstanding, seems to be the extent of the meme community's outlook), we think PLTR stock is a resounding Buy. Fundamentals good, chart good, market improving, whole bunch of retail investors likely to suddenly warm up to the stock once it does start making a move, whole bunch of institutions likely to be buying in during this consolidation period. Buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185975238,"gmtCreate":1623632049124,"gmtModify":1631891633770,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185975238","repostId":"2142204074","repostType":4,"isVote":1,"tweetType":1,"viewCount":357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185975138,"gmtCreate":1623632032324,"gmtModify":1634030989112,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Monitor closely","listText":"Monitor closely","text":"Monitor closely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/185975138","repostId":"1128243947","repostType":4,"isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185976749,"gmtCreate":1623631998281,"gmtModify":1634030990191,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185976749","repostId":"2143857817","repostType":4,"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185976937,"gmtCreate":1623631980829,"gmtModify":1634030991029,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185976937","repostId":"1101883141","repostType":4,"isVote":1,"tweetType":1,"viewCount":248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185059062,"gmtCreate":1623628016856,"gmtModify":1634031103232,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185059062","repostId":"1191179846","repostType":4,"repost":{"id":"1191179846","kind":"news","pubTimestamp":1623536312,"share":"https://www.laohu8.com/m/news/1191179846?lang=&edition=full","pubTime":"2021-06-13 06:18","market":"us","language":"en","title":"Blue Origin auctions seat on first spaceflight with Jeff Bezos for $28 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1191179846","media":"cnbc","summary":"KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed ","content":"<div>\n<p>KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed spaceflight scheduled on July 20.\nThe winning bidder will fly to the edge of space with the Amazon ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blue Origin auctions seat on first spaceflight with Jeff Bezos for $28 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlue Origin auctions seat on first spaceflight with Jeff Bezos for $28 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed spaceflight scheduled on July 20.\nThe winning bidder will fly to the edge of space with the Amazon ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1191179846","content_text":"KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed spaceflight scheduled on July 20.\nThe winning bidder will fly to the edge of space with the Amazon founder and his brother Mark on Blue Origin’s New Shepard rocket.\nNew Shepard, a rocket that carries a capsule to an altitude of over 340,000 feet, has flown more than a dozen successful test flights without passengers.\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat on its upcoming first crewed spaceflight on Saturday for $28 million.\nThe winning bidder,whose name wasn’t released,will fly to the edge of space with theAmazonfounder and his brother Markon Blue Origin’s New Shepard rocket scheduled to launch on July 20.The company said it will reveal the name of the auction winner in the coming weeks.\nBidding opened at $4.8 million but surpassed $20 million within the first few minutes of the auction. The auction’s proceeds will be donated to Blue Origin’s education-focused nonprofit Club for the Future, which supports kids interested in future STEM careers.\nBlue Origin director of astronaut and orbital sales Ariane Cornell said during the auction webcast that New Shepard’s first passenger flight will carry four people, including Bezos, his brother, the auction winner and a fourth person to be announced later.\nAutonomous spaceflight\nNew Shepard, a rocket that carries a capsule to an altitude of over 340,000 feet, has flown more than a dozen successful test flights without passengers, including one in April at the company’s facility in the Texas desert. It’s designed to carry up to six people and flies autonomously — without needing a pilot. The capsule has massive windows to give passengers a view of the earth below during about three minutes in zero gravity, before returning to Earth.\nBlue Origin’s system launches vertically, and both the rocket and capsule are reusable. The boosters land vertically on a concrete pad at the company’s facility in Van Horn, Texas, while the capsules land using a set of parachutes.\nBezos founded Blue Origin in 2000 and still owns the company, funding it through share sales of his Amazon stock.\nJuly 20 is notable because it also marks the 52nd anniversary of the Apollo 11 moon landing.\nBranson and Musk\nBezos and fellow billionairesElon MuskandSir Richard Bransonarein a race to get to space, but each in different ways.Bezos’ Blue Origin and Branson’sVirgin Galacticare competing to take passengers on short flights to the edge of space, a sector known as suborbital tourism, while Musk’s SpaceX is launching private passengers on further, multi-day flights, in what is known as orbital tourism.\nBoth Blue Origin and Virgin Galactic have been developing rocket-powered spacecraft, but that is where the similarities end. While Blue Origin’s New Shepard rocket launches vertically from the ground,Virgin Galactic’s SpaceShipTwo system is released mid-air and returns to Earth in a glidefor a runway landing, like an aircraft.\nVirgin Galactic’s system is also flown by two pilots, while Blue Origin’s launches without one.Branson’s company has also flown a test spaceflight with a passenger onboard, although the company has three spaceflight tests remainingbefore it begins flying commercial customers– which is planned to start in 2022.\nSpaceX launches its Crew Dragon spacecraft to orbit atop its reusable Falcon 9 rocket, havingsent 10 astronauts to the International Space Station on three missions to date.\nIn addition to the government flights, Musk’s company is planning to launch multiple private astronaut missions in the year ahead – beginning withthe all-civilian Inspiration4 missionthat is planned for September. SpaceX is also launchingat least four private missions for Axiom Space, starting early next year.\nBlue Origin’s auction may have netted $28 million, but a seat on a suborbital spacecraft is typically much less expensive. Virgin Galactic has historically sold reservations between $200,000 and $250,000 per ticket, and more recently charged the Italian Air Force about $500,000 per ticket for a training spaceflight.\nMusk’s orbital missions are more costly than the suborbital flights, with NASA paying SpaceX about $55 million per seat for spaceflights to the ISS.","news_type":1},"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185027252,"gmtCreate":1623627968276,"gmtModify":1634031104738,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Awaiting for the game","listText":"Awaiting for the game","text":"Awaiting for the game","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/185027252","repostId":"2143786565","repostType":4,"isVote":1,"tweetType":1,"viewCount":124,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185025683,"gmtCreate":1623627920842,"gmtModify":1634031106548,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Morning","listText":"Morning","text":"Morning","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/185025683","repostId":"2142204074","repostType":4,"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":185025683,"gmtCreate":1623627920842,"gmtModify":1634031106548,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Morning","listText":"Morning","text":"Morning","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/185025683","repostId":"2142204074","repostType":4,"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187215059,"gmtCreate":1623755221371,"gmtModify":1631891633728,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/187215059","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124355260,"gmtCreate":1624748677350,"gmtModify":1631891633656,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/124355260","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187214827,"gmtCreate":1623755261769,"gmtModify":1631891633707,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187214827","repostId":"1122638224","repostType":4,"isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185975138,"gmtCreate":1623632032324,"gmtModify":1634030989112,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Monitor closely","listText":"Monitor closely","text":"Monitor closely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/185975138","repostId":"1128243947","repostType":4,"isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185027252,"gmtCreate":1623627968276,"gmtModify":1634031104738,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Awaiting for the game","listText":"Awaiting for the game","text":"Awaiting for the game","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/185027252","repostId":"2143786565","repostType":4,"isVote":1,"tweetType":1,"viewCount":124,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185977115,"gmtCreate":1623632094237,"gmtModify":1631891633761,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Morning&nbsp;","listText":"Morning&nbsp;","text":"Morning","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185977115","repostId":"1135926549","repostType":4,"repost":{"id":"1135926549","kind":"news","pubTimestamp":1623630467,"share":"https://www.laohu8.com/m/news/1135926549?lang=&edition=full","pubTime":"2021-06-14 08:27","market":"us","language":"en","title":"Palantir Stock In 5 Years: What To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=1135926549","media":"seekingalpha","summary":"Summary\n\nPalantir Technologies, for all the furore surrounding the stock, is simply an enterprise so","content":"<p><b>Summary</b></p>\n<ul>\n <li>Palantir Technologies, for all the furore surrounding the stock, is simply an enterprise software business, and a good one to boot.</li>\n <li>Financial fundamentals are much better than the company is usually given credit for, and the stock price is, we believe, at an attractive buy point.</li>\n <li>In our view, the key with this name is to ignore all the noise on your stock board of choice.</li>\n <li>Looking five years out, we think this stock can be a huge winner, and we hold the name in staff personal accounts as a result.</li>\n <li>We remain at Buy on Palantir.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bb61d2356557cc39d32afc673a3ff65b\" tg-width=\"1536\" tg-height=\"864\" referrerpolicy=\"no-referrer\"><span>kanawatvector/iStock via Getty Images</span></p>\n<p><b>Make Like A Palantirian - Focus On The Signal, Not The Noise</b></p>\n<p>If you talk to users of Palantir Technologies(NYSE:PLTR)software, and we have, they will tell you that the main benefit of the company's technology is that it is able to pull together data from multiple sources and make sense of it all both quickly and easily. It does not require armies of business or data analysts sat in the basement to produce reports digestible by the folks in the big offices on the top floor. This means that correctly deployed, the products offer the dream of analytics companies since the days when \"extract, transform, load\" was new and cool - reduced cost of report production and increased actionability of those reports. Thus far we have yet to talk to a user that didn't think the software had changed their business for the better. No doubt there are some dissatisfied users, but we've yet to speak to any.</p>\n<p>Partly of the management team's own making (\"we love retail investors\"), partly due to the \"master of the dark arts\" reputation the company had fostered during its long gestation period as a privately-owned, CIA-backed business, and partly due to the zeitgeist, Palantir is an incredibly well-followed stock and one that seemingly causes angst amongst shareholders and non-shareholders alike. Just go check your favorite stock board and see the screeching. Our choice of poison is the PLTR board on StockTwits, which ishere. We can use this as an example of the strangely high level of interest in this enterprise software stock. It has 168k followers on that board, which compared to others on the platform is half as many as Microsoft and perhaps of more relevance, more than half as many as the current meme favorite, AMC. And the posts are absolutely breathless. Again, this is an enterprise software company, not an altcoin.</p>\n<p>If you own PLTR stock or are thinking of doing so, our exhortation to you would be to take a step back, calm down, and with a cool head look at the numbers and the stock chart. This is our approach, and it has lead to the name being a high-conviction favorite of ours. When the stock has swooned, we're relaxed; if it moves up in the coming days and weeks, we'll be relaxed. Palantir is, we think, a very strong long term hold stock. If we can leave you with one thought after you read our analysis, it would be: focus on the signal, ignore the noise. And that, after all, is what Palantir Technologies customers pay it to help them do. As a shareholder? The stock can pay you for doing the same.</p>\n<p><b>PLTR Stock Price</b></p>\n<p>Let's first take a look at PLTR's stock price and its evolution since the direct listing last year. It has, in short, been rather volatile.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9c352517d3fdee0325a7ed80cfe61207\" tg-width=\"640\" tg-height=\"379\"><span>Source: YCharts.com</span></p>\n<p>It's the volatility that leads to some of the stock board screeching. But if you just step back you would say that thus far this has been a terrifically successful direct listing, with the stock up 150% since then, versus mid-20s% total returns from the main indices (we use the SPY and QQQ ETFs above as proxies for the S&amp;P500 and the Nasdaq respectively).</p>\n<p>If you look shorter term, since the February 2021 highs, you can see more cause for concern among short-term holders. This chart runs from 1 February this year, to date.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0b6e221de3f33956330342f0010cb029\" tg-width=\"640\" tg-height=\"381\"><span>Source: YCharts.com</span></p>\n<p>Since, inevitably, many people buy near the top of a run, this means there are many holders sat on a loss and hoping for a recovery, and probably many that have sold, absorbing the loss. As always, if you zoom too far in, you can miss the big picture. We believe Palantir stock has a very bright future.</p>\n<p><b>Palantir Valuation</b></p>\n<p>By way of background, here's the numbers on PLTR. The table below is patchy because as a new issue, it takes time for the company's SEC reports to build up a picture of the past. In 3-4 quarters' time we will be able to see a much clearer picture of the quarter-to-quarter history and how the growth flywheel is moving. First, revenue down to EBITDA.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ef965d0aa18087da24ed87c59e9377a\" tg-width=\"505\" tg-height=\"680\"><span>Source: Company SEC filings,YCharts.com, Cestrian Analysis</span></p>\n<p>Now, capex down to net debt and remaining performance obligation.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/07de8f157aa9059c61db0a5fdcacbcc4\" tg-width=\"496\" tg-height=\"411\"><span>Source: Company SEC filings,YCharts.com, Cestrian Analysis</span></p>\n<p>The first half of 2021 has been characterized by a material selloff in growth names, with value stocks being the principal beneficiary. In recent weeks, the market has become a little kinder to growth names and in our house view, that will persist for the remainder of the year. Palantir's valuation multiples have moved up materially of late, which partly reflects the market's warming towards growth names, and partly the improvement in PLTR's own growth rates that you see above.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eade11b880c661731fab7c27c81d528f\" tg-width=\"640\" tg-height=\"378\"><span>Source: YCharts.com</span></p>\n<p>Folks get all steamed up about valuation multiples - is stock X<i>really</i>worth Y times revenue or Z times cashflow? - but in truth, there is no science to it. In a bull market for growth names, the faster you grow and the more profitably you do it and the more visibility you have into future growth, the more expensive your stock, relative to other such stocks. In valuation, everything is relative, there are no absolutes. Ten years ago, paying 10x TTM revenue for a software company was considered expensive, today, plenty trade at 40x TTM revenue plus. It just is what it is.</p>\n<p>Palantir today trades at the following multiples:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddbc7d4aca650c4e6b406c336671ec9b\" tg-width=\"246\" tg-height=\"299\"><span>Source: Company SEC filings, YCharts.com, Cestrian Analysis</span></p>\n<p>The EBITDA and cashflow multiples are clearly absurd if you think that discounted cashflow is any kind of way to measure stock valuations, but since we think DCF is about as relevant to valuing growth names as is the color of the company's logo, we don't take any notice of that. 35x TTM revenue for a business with long-lived government and corporate contracts, the demonstrated ability to generate both accounting and cash profits, and growing revenue at 49% in Q1 vs the prior year Q1? In the current market context that seems fine to us.</p>\n<p><b>Is Palantir A Long-Term Stock?</b></p>\n<p>So, is Palantir a good long-term stock? We find scant assistance from sell-side analyst targets which seem to range from $17-30 looking twelve months out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f3ef1518eb94d1152c976ad16e462bb\" tg-width=\"640\" tg-height=\"223\"><span>Source: TipRanks</span></p>\n<p>We think the answer lies in doing two kinds of actual analysis (as opposed to just deciding the stock might move up a few dollars or down a few dollars which appears to be the basis of price targets!).</p>\n<p><b>Palantir Stock Forecast In 5 Years</b></p>\n<p><b>Fundamental Analysis</b></p>\n<p>The first kind of analysis we think is helpful here is to consider the fundamentals. Here we take the management team's commentary on likely forward growth rates (they target 30% long-run growth), but jacked them<i>up</i>a little because we think the team is sandbagging somewhat. We then assign rising EBITDA margins, cap them at what used to be about right for a well-run enterprise software and services business - 20% - it's quite possible that PLTR can beat this if they hand over much of the services work to consultant partners over time, but let's say 20% terminal EBITDA margins for now. Then we assign a cautious rate of conversion of EBITDA into unlevered pre-tax free cashflow (= EBITDA - capex - change in working capital) such that around 20% of EBITDA leaks into the ether somehow. (This is just a way to model cash generation conservatively. If 20% leaked somewhere it would show up on the balance sheet in poor receivables or huge prepayments or something else. It's a modeling device, it's not real).</p>\n<p>Back to valuation multiples for a moment.</p>\n<p>Where valuation multiples<i>do</i>matter is in the direction of travel between the time you buy a stock and the time you sell it. If multiples expand, that is the greatest source of free money you ever could hope for. Alchemy has nothing on multiple expansion. And if they compress, you can own a company performing wonderfully on its financial statements yet its stock may just not move up at all, or, worse, go down. From a fundamentals perspective, this is the key question long term investors need to ask of PLTR stock. In our house view the company will continue to perform well. The principal risk to returns comes from whether multiples will expand, compress, or stay level. In our 5-year outlook we assume those multiples will tail off somewhat. That's not based on any Fed-whispering, inflation analysis, velocity of money circulation enquiry or anything like that. It's just a modestly cautious modeling device. Multiples could go up a lot, down a lot, stay flat. Who knows. But you have to come up with some assumptions to forecast a stock on fundamentals, so, these are our working assumptions.</p>\n<p>Put all that stuff together could point to a runup from $24 today to $50 or so in 2024, and on to $60 or so in 2025. Now, compared to playingmeme stockswith the best of them, that's not very exciting. But compared to most periods of investing in stocks, doubling your money in three years isn't so bad.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d4e004057976b6da047f994b01b5a99\" tg-width=\"439\" tg-height=\"288\"><span>Source: Company SEC filings,YCharts.com, Cestrian Analysis</span></p>\n<p>From a fundamentals point of view, we see the key risks as fairly simple. One, can the company get out of its own way, meaning, can it execute an increasing pure software model, farming more and more services out to integrator partners. We really do not want to see the company making its numbers by selling consulting time - that's not scalable and is as a result not worth anything like the kinds of multiples above, which assume a software business model. And two, will those multiples hold up. So, quarter to quarter, in our live coverage of the business, that's what we're looking at. Revenue growth vs. gross margin vs. UFCF margins (that tells you all you need to know about the type of revenue and its valuation potential), and, prevailing market multiples for growth names.</p>\n<p><b>Chart Analysis</b></p>\n<p>Chart analysis is particularly relevant to the near term outlook for PLTR and that is itself relevant to the long term, because very often the prevailing view on this name seems to be something highly analytical like, \"it will never see $40 again lol\". The fact that the stock is a little stuck below $25 despite improving fundamentals and a thawing market for growth names isn't any kind of magic. It's just simple demand and supply. The chart below shows you that in that $25 zip code there have been a<i>whole</i>lot of shares traded in the past. And we know that PLTR is a favorite of retail - that 168k follower number above tells you that. And we know that diamond hands are something of a myth among retail investors. When markets drop hard like growth did in H1 2021, then come back, you very often can find folks very happy just to make their money back, or most of it. Relieved, having bought PLTR at say $25-30, folks start selling, because at one point they were looking at a $17 handle and saying, please don't send me a margin call now, pretty please.</p>\n<p>This chart looks horribly complicated, but like all stock charts, it isn't really, once you free your mind and think about what it is telling you about what market participants are doing.</p>\n<p>If you think stock charts are bunk, they aren't. Prepared correctly they can sometimes tell you a<i>lot</i>about the future direction of a stock. So, even if you think this is just some kind of kindergarten coloring-in contest which has gotten carried away with itself, bear with us.</p>\n<p>We think this chart on PLTR is a beauty. Because we think it tells you that with any kind of market tailwind, once PLTR pushes up to $30 or so, it can fly much further. Much further. And since our fundamental analysis tells us that $50-60/share is possible, that our chart says that $30 is surmountable, is another piece of evidence for us that indicates this can be very good long term investment.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/46156df04fcc804d791f980313140d41\" tg-width=\"640\" tg-height=\"299\"><span>Source: TradingView, Cestrian Analysis</span></p>\n<p>Now, if you are an actual technical analyst you can skip what follows because either (1) you already figured it or more likely (2) you have a different and better take on the chart on account of being an actual technical analyst. We aren't technical analysts. We just like messing about with Crayolas. But this is our take:</p>\n<ul>\n <li>This chart shows the whole period from direct listing to today.</li>\n <li>The wide colored horizontal bands show something called the Fibonacci retracement levels. That's a complicated way of saying, if you look at the runup of the stock from its lows to its highs, at what levels on the way back down is it likely to find support? Due to (i) some poorly-understood interlinking between absolute numbers and mammalian brain structure (no, really) and more importantly (ii) the fact that everybody trades according to Fib levels, you can see PLTR find support on the way back down at firstly the 50% retracement (= lost half the value gained on the runup) briefly during February, then it drops quickly to the 61.8% retracement level in late February and hovers around it till early May, whereupon it really starts digging and nearly hits the 78.6% retracement level. That is one big ol selloff, too much by any measure, which is why you see that big, fast reversal on May 11. And allowing for a little oscillation, the stock has moved up since then.</li>\n <li>The upward-sloping thick black line on the right hand side of the chart shows you a rising support level through May and June. The stock is making higher lows each day, which is bullish.</li>\n <li>Now the interesting part. Those blue and yellow lines protruding from right to left tell you the historic volumes of stock traded at any given price. The thick black horizontal line is the \"point of control\" ie. the center of gravity of all those sales. And, lo and behold, between that rising support line and the point of control line, you can see the stock moving up and wanting to punch up through that point of control line. Which is, as you can see, a line of resistance or support stretching back to November 2020. This is why we<i>love</i>stock charts, because of the magic they sometimes reveal.</li>\n <li>Palantir stock is in a firefight between bulls and bears right now. Every time it moves up some, you have a whole lot of people saying, phew and double phew I got my money back or most of it, and selling. And that rush to liquidate is holding up the stock's move upwards. But sooner or later, in our view, the supply of shares for sale will dry up. Because, one, the market is warming to growth names and, two, PLTR is doing well on its fundamentals and is likely to see some improved sentiment around the market. So if the stock can push up to where you see relatively few stocks traded, relatively few disappointed owners - the $30 zone and beyond - then we think the relentless supply of \"for sale\" shares is likely to dry up. And<i>that</i>means the stock can move up much more easily from say $30-40 than it can from $20-30.</li>\n</ul>\n<p>So, our view here is simple. Company fundamentals strong and improving. Market backdrop, warming towards growth names. Stock chart saying, just a little bit further now, just a little more supply of shares-for-sale from \"weak hands\" as the meme fraternity likes to say, and then this stock can really move up.</p>\n<p><b>Is Palantir Stock A Buy, Sell Or Hold Now?</b></p>\n<p>If you bought the stock at $40-something and your best-friend-turned-nemesis broker is calling asking for their margin back, well, you may not have a choice. But if you do have a choice in the matter, and you have a time horizon longer than the weekend (which, diamond hands notwithstanding, seems to be the extent of the meme community's outlook), we think PLTR stock is a resounding Buy. Fundamentals good, chart good, market improving, whole bunch of retail investors likely to suddenly warm up to the stock once it does start making a move, whole bunch of institutions likely to be buying in during this consolidation period. Buy.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir Stock In 5 Years: What To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir Stock In 5 Years: What To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 08:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434399-palantir-stock-5-years><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPalantir Technologies, for all the furore surrounding the stock, is simply an enterprise software business, and a good one to boot.\nFinancial fundamentals are much better than the company is ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434399-palantir-stock-5-years\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4434399-palantir-stock-5-years","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135926549","content_text":"Summary\n\nPalantir Technologies, for all the furore surrounding the stock, is simply an enterprise software business, and a good one to boot.\nFinancial fundamentals are much better than the company is usually given credit for, and the stock price is, we believe, at an attractive buy point.\nIn our view, the key with this name is to ignore all the noise on your stock board of choice.\nLooking five years out, we think this stock can be a huge winner, and we hold the name in staff personal accounts as a result.\nWe remain at Buy on Palantir.\n\nkanawatvector/iStock via Getty Images\nMake Like A Palantirian - Focus On The Signal, Not The Noise\nIf you talk to users of Palantir Technologies(NYSE:PLTR)software, and we have, they will tell you that the main benefit of the company's technology is that it is able to pull together data from multiple sources and make sense of it all both quickly and easily. It does not require armies of business or data analysts sat in the basement to produce reports digestible by the folks in the big offices on the top floor. This means that correctly deployed, the products offer the dream of analytics companies since the days when \"extract, transform, load\" was new and cool - reduced cost of report production and increased actionability of those reports. Thus far we have yet to talk to a user that didn't think the software had changed their business for the better. No doubt there are some dissatisfied users, but we've yet to speak to any.\nPartly of the management team's own making (\"we love retail investors\"), partly due to the \"master of the dark arts\" reputation the company had fostered during its long gestation period as a privately-owned, CIA-backed business, and partly due to the zeitgeist, Palantir is an incredibly well-followed stock and one that seemingly causes angst amongst shareholders and non-shareholders alike. Just go check your favorite stock board and see the screeching. Our choice of poison is the PLTR board on StockTwits, which ishere. We can use this as an example of the strangely high level of interest in this enterprise software stock. It has 168k followers on that board, which compared to others on the platform is half as many as Microsoft and perhaps of more relevance, more than half as many as the current meme favorite, AMC. And the posts are absolutely breathless. Again, this is an enterprise software company, not an altcoin.\nIf you own PLTR stock or are thinking of doing so, our exhortation to you would be to take a step back, calm down, and with a cool head look at the numbers and the stock chart. This is our approach, and it has lead to the name being a high-conviction favorite of ours. When the stock has swooned, we're relaxed; if it moves up in the coming days and weeks, we'll be relaxed. Palantir is, we think, a very strong long term hold stock. If we can leave you with one thought after you read our analysis, it would be: focus on the signal, ignore the noise. And that, after all, is what Palantir Technologies customers pay it to help them do. As a shareholder? The stock can pay you for doing the same.\nPLTR Stock Price\nLet's first take a look at PLTR's stock price and its evolution since the direct listing last year. It has, in short, been rather volatile.\nSource: YCharts.com\nIt's the volatility that leads to some of the stock board screeching. But if you just step back you would say that thus far this has been a terrifically successful direct listing, with the stock up 150% since then, versus mid-20s% total returns from the main indices (we use the SPY and QQQ ETFs above as proxies for the S&P500 and the Nasdaq respectively).\nIf you look shorter term, since the February 2021 highs, you can see more cause for concern among short-term holders. This chart runs from 1 February this year, to date.\nSource: YCharts.com\nSince, inevitably, many people buy near the top of a run, this means there are many holders sat on a loss and hoping for a recovery, and probably many that have sold, absorbing the loss. As always, if you zoom too far in, you can miss the big picture. We believe Palantir stock has a very bright future.\nPalantir Valuation\nBy way of background, here's the numbers on PLTR. The table below is patchy because as a new issue, it takes time for the company's SEC reports to build up a picture of the past. In 3-4 quarters' time we will be able to see a much clearer picture of the quarter-to-quarter history and how the growth flywheel is moving. First, revenue down to EBITDA.\nSource: Company SEC filings,YCharts.com, Cestrian Analysis\nNow, capex down to net debt and remaining performance obligation.\nSource: Company SEC filings,YCharts.com, Cestrian Analysis\nThe first half of 2021 has been characterized by a material selloff in growth names, with value stocks being the principal beneficiary. In recent weeks, the market has become a little kinder to growth names and in our house view, that will persist for the remainder of the year. Palantir's valuation multiples have moved up materially of late, which partly reflects the market's warming towards growth names, and partly the improvement in PLTR's own growth rates that you see above.\nSource: YCharts.com\nFolks get all steamed up about valuation multiples - is stock Xreallyworth Y times revenue or Z times cashflow? - but in truth, there is no science to it. In a bull market for growth names, the faster you grow and the more profitably you do it and the more visibility you have into future growth, the more expensive your stock, relative to other such stocks. In valuation, everything is relative, there are no absolutes. Ten years ago, paying 10x TTM revenue for a software company was considered expensive, today, plenty trade at 40x TTM revenue plus. It just is what it is.\nPalantir today trades at the following multiples:\nSource: Company SEC filings, YCharts.com, Cestrian Analysis\nThe EBITDA and cashflow multiples are clearly absurd if you think that discounted cashflow is any kind of way to measure stock valuations, but since we think DCF is about as relevant to valuing growth names as is the color of the company's logo, we don't take any notice of that. 35x TTM revenue for a business with long-lived government and corporate contracts, the demonstrated ability to generate both accounting and cash profits, and growing revenue at 49% in Q1 vs the prior year Q1? In the current market context that seems fine to us.\nIs Palantir A Long-Term Stock?\nSo, is Palantir a good long-term stock? We find scant assistance from sell-side analyst targets which seem to range from $17-30 looking twelve months out.\nSource: TipRanks\nWe think the answer lies in doing two kinds of actual analysis (as opposed to just deciding the stock might move up a few dollars or down a few dollars which appears to be the basis of price targets!).\nPalantir Stock Forecast In 5 Years\nFundamental Analysis\nThe first kind of analysis we think is helpful here is to consider the fundamentals. Here we take the management team's commentary on likely forward growth rates (they target 30% long-run growth), but jacked themupa little because we think the team is sandbagging somewhat. We then assign rising EBITDA margins, cap them at what used to be about right for a well-run enterprise software and services business - 20% - it's quite possible that PLTR can beat this if they hand over much of the services work to consultant partners over time, but let's say 20% terminal EBITDA margins for now. Then we assign a cautious rate of conversion of EBITDA into unlevered pre-tax free cashflow (= EBITDA - capex - change in working capital) such that around 20% of EBITDA leaks into the ether somehow. (This is just a way to model cash generation conservatively. If 20% leaked somewhere it would show up on the balance sheet in poor receivables or huge prepayments or something else. It's a modeling device, it's not real).\nBack to valuation multiples for a moment.\nWhere valuation multiplesdomatter is in the direction of travel between the time you buy a stock and the time you sell it. If multiples expand, that is the greatest source of free money you ever could hope for. Alchemy has nothing on multiple expansion. And if they compress, you can own a company performing wonderfully on its financial statements yet its stock may just not move up at all, or, worse, go down. From a fundamentals perspective, this is the key question long term investors need to ask of PLTR stock. In our house view the company will continue to perform well. The principal risk to returns comes from whether multiples will expand, compress, or stay level. In our 5-year outlook we assume those multiples will tail off somewhat. That's not based on any Fed-whispering, inflation analysis, velocity of money circulation enquiry or anything like that. It's just a modestly cautious modeling device. Multiples could go up a lot, down a lot, stay flat. Who knows. But you have to come up with some assumptions to forecast a stock on fundamentals, so, these are our working assumptions.\nPut all that stuff together could point to a runup from $24 today to $50 or so in 2024, and on to $60 or so in 2025. Now, compared to playingmeme stockswith the best of them, that's not very exciting. But compared to most periods of investing in stocks, doubling your money in three years isn't so bad.\nSource: Company SEC filings,YCharts.com, Cestrian Analysis\nFrom a fundamentals point of view, we see the key risks as fairly simple. One, can the company get out of its own way, meaning, can it execute an increasing pure software model, farming more and more services out to integrator partners. We really do not want to see the company making its numbers by selling consulting time - that's not scalable and is as a result not worth anything like the kinds of multiples above, which assume a software business model. And two, will those multiples hold up. So, quarter to quarter, in our live coverage of the business, that's what we're looking at. Revenue growth vs. gross margin vs. UFCF margins (that tells you all you need to know about the type of revenue and its valuation potential), and, prevailing market multiples for growth names.\nChart Analysis\nChart analysis is particularly relevant to the near term outlook for PLTR and that is itself relevant to the long term, because very often the prevailing view on this name seems to be something highly analytical like, \"it will never see $40 again lol\". The fact that the stock is a little stuck below $25 despite improving fundamentals and a thawing market for growth names isn't any kind of magic. It's just simple demand and supply. The chart below shows you that in that $25 zip code there have been awholelot of shares traded in the past. And we know that PLTR is a favorite of retail - that 168k follower number above tells you that. And we know that diamond hands are something of a myth among retail investors. When markets drop hard like growth did in H1 2021, then come back, you very often can find folks very happy just to make their money back, or most of it. Relieved, having bought PLTR at say $25-30, folks start selling, because at one point they were looking at a $17 handle and saying, please don't send me a margin call now, pretty please.\nThis chart looks horribly complicated, but like all stock charts, it isn't really, once you free your mind and think about what it is telling you about what market participants are doing.\nIf you think stock charts are bunk, they aren't. Prepared correctly they can sometimes tell you alotabout the future direction of a stock. So, even if you think this is just some kind of kindergarten coloring-in contest which has gotten carried away with itself, bear with us.\nWe think this chart on PLTR is a beauty. Because we think it tells you that with any kind of market tailwind, once PLTR pushes up to $30 or so, it can fly much further. Much further. And since our fundamental analysis tells us that $50-60/share is possible, that our chart says that $30 is surmountable, is another piece of evidence for us that indicates this can be very good long term investment.\nSource: TradingView, Cestrian Analysis\nNow, if you are an actual technical analyst you can skip what follows because either (1) you already figured it or more likely (2) you have a different and better take on the chart on account of being an actual technical analyst. We aren't technical analysts. We just like messing about with Crayolas. But this is our take:\n\nThis chart shows the whole period from direct listing to today.\nThe wide colored horizontal bands show something called the Fibonacci retracement levels. That's a complicated way of saying, if you look at the runup of the stock from its lows to its highs, at what levels on the way back down is it likely to find support? Due to (i) some poorly-understood interlinking between absolute numbers and mammalian brain structure (no, really) and more importantly (ii) the fact that everybody trades according to Fib levels, you can see PLTR find support on the way back down at firstly the 50% retracement (= lost half the value gained on the runup) briefly during February, then it drops quickly to the 61.8% retracement level in late February and hovers around it till early May, whereupon it really starts digging and nearly hits the 78.6% retracement level. That is one big ol selloff, too much by any measure, which is why you see that big, fast reversal on May 11. And allowing for a little oscillation, the stock has moved up since then.\nThe upward-sloping thick black line on the right hand side of the chart shows you a rising support level through May and June. The stock is making higher lows each day, which is bullish.\nNow the interesting part. Those blue and yellow lines protruding from right to left tell you the historic volumes of stock traded at any given price. The thick black horizontal line is the \"point of control\" ie. the center of gravity of all those sales. And, lo and behold, between that rising support line and the point of control line, you can see the stock moving up and wanting to punch up through that point of control line. Which is, as you can see, a line of resistance or support stretching back to November 2020. This is why welovestock charts, because of the magic they sometimes reveal.\nPalantir stock is in a firefight between bulls and bears right now. Every time it moves up some, you have a whole lot of people saying, phew and double phew I got my money back or most of it, and selling. And that rush to liquidate is holding up the stock's move upwards. But sooner or later, in our view, the supply of shares for sale will dry up. Because, one, the market is warming to growth names and, two, PLTR is doing well on its fundamentals and is likely to see some improved sentiment around the market. So if the stock can push up to where you see relatively few stocks traded, relatively few disappointed owners - the $30 zone and beyond - then we think the relentless supply of \"for sale\" shares is likely to dry up. Andthatmeans the stock can move up much more easily from say $30-40 than it can from $20-30.\n\nSo, our view here is simple. Company fundamentals strong and improving. Market backdrop, warming towards growth names. Stock chart saying, just a little bit further now, just a little more supply of shares-for-sale from \"weak hands\" as the meme fraternity likes to say, and then this stock can really move up.\nIs Palantir Stock A Buy, Sell Or Hold Now?\nIf you bought the stock at $40-something and your best-friend-turned-nemesis broker is calling asking for their margin back, well, you may not have a choice. But if you do have a choice in the matter, and you have a time horizon longer than the weekend (which, diamond hands notwithstanding, seems to be the extent of the meme community's outlook), we think PLTR stock is a resounding Buy. Fundamentals good, chart good, market improving, whole bunch of retail investors likely to suddenly warm up to the stock once it does start making a move, whole bunch of institutions likely to be buying in during this consolidation period. Buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185059062,"gmtCreate":1623628016856,"gmtModify":1634031103232,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185059062","repostId":"1191179846","repostType":4,"repost":{"id":"1191179846","kind":"news","pubTimestamp":1623536312,"share":"https://www.laohu8.com/m/news/1191179846?lang=&edition=full","pubTime":"2021-06-13 06:18","market":"us","language":"en","title":"Blue Origin auctions seat on first spaceflight with Jeff Bezos for $28 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1191179846","media":"cnbc","summary":"KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed ","content":"<div>\n<p>KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed spaceflight scheduled on July 20.\nThe winning bidder will fly to the edge of space with the Amazon ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blue Origin auctions seat on first spaceflight with Jeff Bezos for $28 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlue Origin auctions seat on first spaceflight with Jeff Bezos for $28 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed spaceflight scheduled on July 20.\nThe winning bidder will fly to the edge of space with the Amazon ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.cnbc.com/2021/06/12/jeff-bezos-blue-origin-auctions-spaceflight-seat-for-28-million.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1191179846","content_text":"KEY POINTS\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat Saturday on its first crewed spaceflight scheduled on July 20.\nThe winning bidder will fly to the edge of space with the Amazon founder and his brother Mark on Blue Origin’s New Shepard rocket.\nNew Shepard, a rocket that carries a capsule to an altitude of over 340,000 feet, has flown more than a dozen successful test flights without passengers.\n\nJeff Bezos’ space venture Blue Origin auctioned off a seat on its upcoming first crewed spaceflight on Saturday for $28 million.\nThe winning bidder,whose name wasn’t released,will fly to the edge of space with theAmazonfounder and his brother Markon Blue Origin’s New Shepard rocket scheduled to launch on July 20.The company said it will reveal the name of the auction winner in the coming weeks.\nBidding opened at $4.8 million but surpassed $20 million within the first few minutes of the auction. The auction’s proceeds will be donated to Blue Origin’s education-focused nonprofit Club for the Future, which supports kids interested in future STEM careers.\nBlue Origin director of astronaut and orbital sales Ariane Cornell said during the auction webcast that New Shepard’s first passenger flight will carry four people, including Bezos, his brother, the auction winner and a fourth person to be announced later.\nAutonomous spaceflight\nNew Shepard, a rocket that carries a capsule to an altitude of over 340,000 feet, has flown more than a dozen successful test flights without passengers, including one in April at the company’s facility in the Texas desert. It’s designed to carry up to six people and flies autonomously — without needing a pilot. The capsule has massive windows to give passengers a view of the earth below during about three minutes in zero gravity, before returning to Earth.\nBlue Origin’s system launches vertically, and both the rocket and capsule are reusable. The boosters land vertically on a concrete pad at the company’s facility in Van Horn, Texas, while the capsules land using a set of parachutes.\nBezos founded Blue Origin in 2000 and still owns the company, funding it through share sales of his Amazon stock.\nJuly 20 is notable because it also marks the 52nd anniversary of the Apollo 11 moon landing.\nBranson and Musk\nBezos and fellow billionairesElon MuskandSir Richard Bransonarein a race to get to space, but each in different ways.Bezos’ Blue Origin and Branson’sVirgin Galacticare competing to take passengers on short flights to the edge of space, a sector known as suborbital tourism, while Musk’s SpaceX is launching private passengers on further, multi-day flights, in what is known as orbital tourism.\nBoth Blue Origin and Virgin Galactic have been developing rocket-powered spacecraft, but that is where the similarities end. While Blue Origin’s New Shepard rocket launches vertically from the ground,Virgin Galactic’s SpaceShipTwo system is released mid-air and returns to Earth in a glidefor a runway landing, like an aircraft.\nVirgin Galactic’s system is also flown by two pilots, while Blue Origin’s launches without one.Branson’s company has also flown a test spaceflight with a passenger onboard, although the company has three spaceflight tests remainingbefore it begins flying commercial customers– which is planned to start in 2022.\nSpaceX launches its Crew Dragon spacecraft to orbit atop its reusable Falcon 9 rocket, havingsent 10 astronauts to the International Space Station on three missions to date.\nIn addition to the government flights, Musk’s company is planning to launch multiple private astronaut missions in the year ahead – beginning withthe all-civilian Inspiration4 missionthat is planned for September. SpaceX is also launchingat least four private missions for Axiom Space, starting early next year.\nBlue Origin’s auction may have netted $28 million, but a seat on a suborbital spacecraft is typically much less expensive. Virgin Galactic has historically sold reservations between $200,000 and $250,000 per ticket, and more recently charged the Italian Air Force about $500,000 per ticket for a training spaceflight.\nMusk’s orbital missions are more costly than the suborbital flights, with NASA paying SpaceX about $55 million per seat for spaceflights to the ISS.","news_type":1},"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124359059,"gmtCreate":1624748159971,"gmtModify":1631891633671,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124359059","repostId":"1198714523","repostType":2,"isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185975238,"gmtCreate":1623632049124,"gmtModify":1631891633770,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185975238","repostId":"2142204074","repostType":4,"isVote":1,"tweetType":1,"viewCount":357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151694788,"gmtCreate":1625077624644,"gmtModify":1631891633641,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"This is my reward&nbsp;","listText":"This is my reward&nbsp;","text":"This is my reward","images":[{"img":"https://static.tigerbbs.com/2f99972d9d6d60790b46f7bec41f4e14","width":"750","height":"1238"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151694788","isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":187217979,"gmtCreate":1623755280491,"gmtModify":1631891633691,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187217979","repostId":"1184288080","repostType":4,"isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187215232,"gmtCreate":1623755239526,"gmtModify":1631891633721,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187215232","repostId":"1114926830","repostType":4,"isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187212117,"gmtCreate":1623755201339,"gmtModify":1631891633745,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187212117","repostId":"1135158450","repostType":4,"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185976749,"gmtCreate":1623631998281,"gmtModify":1634030990191,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185976749","repostId":"2143857817","repostType":4,"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185976937,"gmtCreate":1623631980829,"gmtModify":1634030991029,"author":{"id":"3583732088443383","authorId":"3583732088443383","name":"TanHL","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583732088443383","authorIdStr":"3583732088443383"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185976937","repostId":"1101883141","repostType":4,"isVote":1,"tweetType":1,"viewCount":248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}